

# Epidemiology, Pathology and Breast Cancer Risk

Mary Beth Terry, PhD

Department of Epidemiology

Mailman School of Public Health

Columbia University

Discover. Educate. Care. Lead.





# Breast Cancer: A Heterogeneous Disease





#### Risk Factors by Hormone Receptor Status and Histologic Type

	Hormone Receptors	Histologic Type			
Risk Factors					
Reproductive factors	+/ -	Ductal ++, Lobular +			
Increased BMI	HR +	Ductal ++, Lobular +			
Alcohol drinking	HR +	Lobular ++, Ductal +			
Cigarette smoking	+/ -				
OC use	+/ -	Lobular +			
HRT use	HR +	Lobular ++, Ductal +			
Aspirin use	HR +				
Family history	+/ -	Medullary			
Demographic Characteristics					
Younger age	HR –	Medullary			
nonwhite	HR -	Medullary, Mucinous			



# HRT use and Breast Cancer Risk by Histologic Type

#### **Duration of HRT Use**

Ever vs. Never	6m-5y vs. Never
■ 5-15y vs. Never	<mark>■</mark> ≥15y vs. Never



975 invasive breast cancer cases and 1007 population-based controls

□ Combined estrogen and progestin HRT use

Risk of invasive lobular and ductal breast carcinomas associated with HRT use

HRT use is associated with BC risk, particularly invasive lobular tumors

(Li Cl et al 2005 JAMA)



# Aspirin Use and Breast Cancer Risk by Hormone Receptor Status



□ Long Island Breast Cancer Study; 1442 cases and 1420 controls provided NSAIDs use data

□ Ever use aspirin 1/wk for ≥ 6 month

□ Risk of BC associated with aspirin intake by hormone receptor status

□ Inverse association between aspirin and BC risk only among hormone receptor positive tumors

(Terry MB et al 2004 JAMA)



#### **Breast Cancer Risk Factors by Molecular Phenotypes**

Study Design	1			
Population-based case-control study (509 Cases and 462 Controls)				
Conducted in New Jersey b/w 1990-92				
Tissue block available for 78.8% of cases				
In-person interview with women under age 45 yrs				
Study Results				
Smoking by p53 expression				
OC use by Her2neu expression				
OC use by Cyclins expression				
Breast cancer survival by Cyclins expression				
1 *				



# Survival of Breast Cancer Cases by Joint Cyclin D1 and E Status





# **Ever OC Use and Breast Cancer Risk by Cyclin** D1 and E status



OC use (Ever vs. Never)



#### **Duration of OC Use and Breast Cancer Risk by Cyclin E status**



Duration of OC use



# **Competing Hypotheses**







## **Distribution of Histologic Types**

	Australia (N=574)	Ontario (N=1215)	California (N=1165)	Total (N=2646)
Ductal, NOS	77%	71 %	83 %	76 %
Lobular	16%	19 %	7 %	15 %
Medullary	3%	3 %	4 %	3 %
Tubular	2%	3 %	2 %	2 %
Mucinous	1%	3 %	3 %	3 %
Others	1%	2 %	1 %	1 %





# Summary

- 1) Molecular signatures of exposure (e.g., aflatoxin and liver cancer)?
  - 1)Molecular phenotype
    - a) oligo-phenotype
    - b) global expression arrays
  - 2) Histology
  - 3) Null finding would be informative as well
- 2) Impact on cancer prevention



# Acknowledgements

- Fang Fang Zhang, M.D.
- Hanina Hibshoosh, M.D.
- Frances O'Malley, M.D.
- Analytic Working Group
- **Breast -CFR**
- New Jersey Study: Marilie Gammon, Ph.D.
- K07 National Cancer Institute



#### Identification of pathology and ER/PR status





#### **Smoking and Breast Cancer Risk by Histologic Type**

Smoking (Ever vs. Never)





### Parity, Alcohol Drinking and OC use Associated with Breast Cancer Risk by Hormonal Receptor Status



≥1 Positive Hormone Receptors vs. No Positive Hormone Receptors

